News for Cara Therapeutics, Inc. (0HTC.L)

PR NewswireNEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

**media[501337]**

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. ( CARA) (the ”œCompany”), today announced that a 1-for-12 reverse stock split of

PR NewswireNEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed

Cara Therapeutics, Inc. (CARA), Wednesday announced that the company has entered into a merger agreement with Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company.

Cara Therapeutics Announces Exploration of Strategic Alternatives Cara Therapeutics, Inc. (Nasdaq: CARA)…

Loading... Loading... U.S. stocks traded mixed toward the end of trading, with the S&P 500 edging higher on Thursday. The Dow traded down 0.21% to 38,629.82 w...

Loading... Loading... Shares of Signet Jewelers Limited SIG fell sharply during Thursday's session following mixed first-quarter earnings including an 8.9% dro...

Loading... Loading... U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping by more than 200 points on Thursday. The Dow traded do...

Loading... Loading... Shares of Broadcom Inc. AVGO rose sharply in today's pre-market trading after the company posted stronger-than-expected results for its s...

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic castration-resistant prostate cancer.

On Wednesday, 311 stocks hit new 52-week lows.

Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for…

Cara Therapeutics, Inc. (CARA), a commercial-stage biopharmaceutical company focused on pruritus, announced Monday the Approval of KORSUVA IV Injection Syringe in Japan to treat pruritus in hemodialysis patients.

Approval triggers $1.5 million milestone payment to Cara...

Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors Cara Therapeutics,…

STAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new...

/PRNewswire/ -- The "Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to...